JP6706262B2 - 毛包虫症治療のためのイソオキサゾリン化合物の使用 - Google Patents

毛包虫症治療のためのイソオキサゾリン化合物の使用 Download PDF

Info

Publication number
JP6706262B2
JP6706262B2 JP2017533378A JP2017533378A JP6706262B2 JP 6706262 B2 JP6706262 B2 JP 6706262B2 JP 2017533378 A JP2017533378 A JP 2017533378A JP 2017533378 A JP2017533378 A JP 2017533378A JP 6706262 B2 JP6706262 B2 JP 6706262B2
Authority
JP
Japan
Prior art keywords
isoxazoline compound
treatment
dogs
use according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017533378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538767A (ja
JP2017538767A5 (enExample
Inventor
ウィリアムズ,ハイケ
へクロス,アンニャ・レジーナ
テンツラー,ヤニーナ
フルネ,レジス・ジョエル・アラン
Original Assignee
インターベット インターナショナル ベー. フェー.
インターベット インターナショナル ベー. フェー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6706262(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by インターベット インターナショナル ベー. フェー., インターベット インターナショナル ベー. フェー. filed Critical インターベット インターナショナル ベー. フェー.
Publication of JP2017538767A publication Critical patent/JP2017538767A/ja
Publication of JP2017538767A5 publication Critical patent/JP2017538767A5/ja
Application granted granted Critical
Publication of JP6706262B2 publication Critical patent/JP6706262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2017533378A 2014-12-22 2015-12-21 毛包虫症治療のためのイソオキサゾリン化合物の使用 Active JP6706262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199562 2014-12-22
EP14199562.1 2014-12-22
PCT/EP2015/080744 WO2016102437A1 (en) 2014-12-22 2015-12-21 Use of isoxazoline compounds for treating demodicosis

Publications (3)

Publication Number Publication Date
JP2017538767A JP2017538767A (ja) 2017-12-28
JP2017538767A5 JP2017538767A5 (enExample) 2019-01-24
JP6706262B2 true JP6706262B2 (ja) 2020-06-03

Family

ID=52146273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533378A Active JP6706262B2 (ja) 2014-12-22 2015-12-21 毛包虫症治療のためのイソオキサゾリン化合物の使用

Country Status (14)

Country Link
US (3) US20170348286A1 (enExample)
EP (3) EP4008329B1 (enExample)
JP (1) JP6706262B2 (enExample)
CN (2) CN106999475B (enExample)
AU (3) AU2015371175B2 (enExample)
BR (1) BR112017013286A2 (enExample)
CA (1) CA2971296A1 (enExample)
DK (2) DK4008329T3 (enExample)
ES (2) ES3037078T3 (enExample)
FI (2) FI3236960T3 (enExample)
PL (2) PL4008329T3 (enExample)
PT (2) PT4008329T (enExample)
RU (1) RU2709198C2 (enExample)
WO (1) WO2016102437A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
DK4008329T3 (da) 2014-12-22 2025-08-18 Intervet Int Bv Isoxazolinforbindelser til anvendelse i behandling af demodicose
WO2018039508A1 (en) * 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
CN107501199A (zh) * 2017-08-16 2017-12-22 南京农业大学 氟雷拉纳单体化合物的提取和纯化方法
CN119157876A (zh) * 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US11880349B2 (en) 2019-04-30 2024-01-23 Salesforce, Inc. System or method to query or search a metadata driven distributed ledger or blockchain
JP2022537389A (ja) * 2019-06-19 2022-08-25 ターサス ファーマシューティカルズ, インコーポレイテッド 眼瞼炎を治療するためのイソキサゾリン寄生虫駆除剤の処方及び方法
US12497370B2 (en) 2019-12-18 2025-12-16 Elanco Tiergesundheit Ag Isoxazoline derivatives
US12655138B2 (en) 2020-07-24 2026-06-16 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
CN115785017B (zh) * 2022-12-06 2023-12-08 海利尔药业集团股份有限公司 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067863C1 (ru) * 1994-05-25 1996-10-20 Казанский государственный технологический университет Акарицидный состав для лечения чесотки домашних животных
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
TWI412322B (zh) 2005-12-30 2013-10-21 杜邦股份有限公司 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
DK2182945T3 (en) 2007-06-27 2015-11-16 Du Pont PROCEDURE TO COMBAT PESTS WITH ANIMALS
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
ES2442342T3 (es) 2008-12-18 2014-02-11 Novartis Ag Derivados de las isoxazolinas y su uso como pesticida
AR074790A1 (es) * 2008-12-19 2011-02-09 Novartis Ag Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente.
JP6002148B2 (ja) 2010-12-27 2016-10-05 インターベット インターナショナル ベー. フェー. 経表面局所イソオキサゾリン製剤
CN103260620A (zh) 2010-12-27 2013-08-21 英特维特国际股份有限公司 包含三缩四乙二醇的外用局部异噁唑啉制剂
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
HUE042360T2 (hu) * 2011-09-12 2019-06-28 Merial Inc Izoxazolin hatóanyagot tartalmazó parazitaellenes készítmények, ezek elõállítása és alkalmazása
AP2014007874A0 (en) 2012-02-06 2014-08-31 Merial Ltd Parasiticidal oral veterinary compositions comprising systemetically- acting active agents, methods and uses thereof
CN108685894B (zh) 2012-04-04 2022-04-26 英特维特国际股份有限公司 软咀嚼药用产品
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
MX373872B (es) * 2013-12-20 2020-03-26 Intervet Int Bv Composiciones de isoxazolina y uso de las mismas en la prevención o tratamiento de infestaciones parasitarias en animales.
DK4008329T3 (da) 2014-12-22 2025-08-18 Intervet Int Bv Isoxazolinforbindelser til anvendelse i behandling af demodicose

Also Published As

Publication number Publication date
EP4008329A1 (en) 2022-06-08
CN114681453A (zh) 2022-07-01
EP4008329B1 (en) 2025-06-11
CN106999475B (zh) 2022-10-25
US10799483B2 (en) 2020-10-13
AU2023219972B2 (en) 2025-05-29
US20200405692A1 (en) 2020-12-31
AU2015371175A1 (en) 2017-06-15
BR112017013286A2 (pt) 2018-03-06
PT4008329T (pt) 2025-07-30
DK3236960T3 (da) 2025-03-31
CA2971296A1 (en) 2016-06-30
FI3236960T3 (fi) 2025-04-05
EP3236960A1 (en) 2017-11-01
EP4599830A3 (en) 2025-11-19
WO2016102437A1 (en) 2016-06-30
JP2017538767A (ja) 2017-12-28
US20170348286A1 (en) 2017-12-07
PL3236960T3 (pl) 2025-07-07
AU2021203686A1 (en) 2021-07-01
PL4008329T3 (pl) 2025-11-17
DK4008329T3 (da) 2025-08-18
AU2023219972A1 (en) 2023-09-14
RU2017126029A (ru) 2019-01-24
PT3236960T (pt) 2025-04-08
RU2017126029A3 (enExample) 2019-06-20
ES3037078T3 (en) 2025-09-26
ES3018234T3 (en) 2025-05-14
US20180318265A1 (en) 2018-11-08
EP3236960B1 (en) 2025-01-29
RU2709198C2 (ru) 2019-12-17
AU2015371175B2 (en) 2021-03-04
FI4008329T3 (fi) 2025-08-22
EP4599830A2 (en) 2025-08-13
CN106999475A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
AU2023219972B2 (en) Use of isoxazoline compounds for treating demodicosis
EP3079474B1 (en) Antiparasitic use of isoxazoline compounds
US20200390688A1 (en) Long-acting topical formulation and method of use thereof
Hamel et al. Treatment and control of bovine sarcoptic and psoroptic mange infestation with ivermectin long-acting injectable (IVOMEC® GOLD)
WO2022258797A1 (en) Tick control methods
AU2024278148A1 (en) Parasite control in ruminants
US11903962B1 (en) Isoxazoline complexes and compositions thereof
HUP0101347A2 (hu) Eljárás parazitafertőzés kezelésére
Kumar et al. Drugs for therapeutic application in goat
US20240366572A1 (en) Isoxazoline complexes and compositions thereof
RU2772279C2 (ru) Твердые фармацевтические композиции для перорального введения на основе изоксазолиновых соединений
WO2012010701A1 (en) Composition for the treatment of botulism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200515

R150 Certificate of patent or registration of utility model

Ref document number: 6706262

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250